Percutaneous tibial nerve stimulation versus tolterodine for overactive bladder in women: a randomised controlled trial. (August 2015)

• Record Type: Journal Article
• Authors: Preyer, Oliver; Umek, Wolfgang; Laml, Thomas; Bjelic-Radisic, Vesna; Gabriel, Boris; Mittlboeck, Martina; Hanzal, Engelbert
• Is Part Of: European journal of obstetrics, gynecology, and reproductive biology. Volume 191(2015:Aug.)
• Page Start: 51
• Page End: 56
• Publication Date: 2015-08
• Subjects: OAB overactive bladder syndrome -- PTNS percutaneous tibial nerve stimulation -- RCT randomised controlled trial -- QoL quality of life -- VAS visual analogue scale -- p.o. per os -- SAE serious adverse event -- EC ethics committee -- ICS International Continence Society -- SD standard deviation -- SNS sacral neurostimulation; Overactive bladder -- Percutaneous tibial nerve stimulation (PTNS) -- Side effects -- Tolterodine; Obstetrics -- Periodicals; Gynecology -- Periodicals; Reproductive health -- Periodicals; Gynecology -- Periodicals; Obstetrics -- Periodicals; Reproduction -- Periodicals; Obstétrique -- Périodiques; Gynécologie -- Périodiques; Reproduction -- Périodiques; Verloskunde; Gynaecologie; Voortplanting (biologie); Gynecology; Obstetrics; Reproduction; Electronic journals; Periodicals; Electronic journals; 618.05
• DOI: 10.1016/j.ejogrb.2015.05.014
• Languages: English
• ISSNs: 0301-2115

Abstract

Abstract: Objective: We performed a randomised controlled trial of percutaneous tibial nerve stimulation (PTNS) versus tolterodine for treating treatment naïve women with overactive bladder (OAB). Study design: 36 patients with symptoms of OAB were randomised to 3 months of treatment with weekly PTNS or tolterodine (2 mg bid p.o.). The primary outcome measure was the difference of micturitions per 24 h. The secondary outcome measure was the impact on quality of life (QoL) measured with a visual analogue scale (VAS) between baseline and after 3 months of therapy. Results: Micturition frequencies did not decline significantly ( p = 0.13) over time and there were no significant treatment differences ( p = 0.96). QoL was significantly dependent from its level at baseline ( p = 0.002) and showed improvement over time compared to baseline measurements but no significant differences between both treatment groups ( p = 0.07). Incontinence episodes per 24 h depended significantly on the level at baseline ( p = 0.0001) and declined significantly ( p = 0.03) during 3 months of therapy in both therapy groups. However no significant treatment differences on the reduction of incontinence episodes in 24 h could be shown between both therapy groups ( p = 0.89). PTNS had fewer side effects than tolterodine ( p = 0.04). Conclusion: PTNS and tolterodine were both effective in reducing incontinence episodes and improving QoL in patients with OAB but not micturition frequencies. PTNS had fewer side effects.